Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma Clinical Trial
Official title:
A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
| Verified date | May 2023 |
| Source | Amgen |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is a phase 2, multicenter, randomized, open-label study to estimate the efficacy of talimogene laherparepvec as a neoadjuvant treatment followed by surgery compared to surgery alone in subjects with completely resectable stage IIIB, IIIC, or IVM1a melanoma.
| Status | Completed |
| Enrollment | 150 |
| Est. completion date | April 28, 2022 |
| Est. primary completion date | April 30, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Histologically confirmed diagnosis of stage IIIB, IIIC or IVM1a melanoma eligible for complete surgical resection. - Prior systemic, regional and radiation anticancer therapies for melanoma must have been completed at least 3 months prior to randomization. - Subject must have measurable disease and must be a candidate for intralesional therapy with at least one injectable cutaneous, subcutaneous, or nodal melanoma lesion (= 10 mm in longest diameter) or with multiple injectable lesions that in aggregate have a longest diameter of = 10 mm. - Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and must have a serum lactate dehydrogenase (LDH) = 1.0 X upper limit of normal and adequate hematologic, hepatic, renal, and coagulation organ function- Other criteria may apply Exclusion Criteria: - Subject must not have primary ocular or mucosal melanoma, or history or evidence of melanoma associated with immunodeficiency states (eg, hereditary immune deficiency, organ transplant, or leukemia). - Subject must not have history or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other symptomatic autoimmune disease. - Subject must not have evidence of clinically significant immunosuppression or active herpetic skin lesions or prior complications of herpes simplex type 1 (HSV-1) infection (eg, herpetic keratitis or encephalitis) and must not require intermittent or chronic systemic treatment with an antiherpetic drug (eg, acyclovir), other than intermittent topical use. - Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded. - Subject must not have been treated previously with talimogene laherparepvec or tumor vaccine. Other criteria may apply |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Research Site | Heidelberg | Victoria |
| Australia | Research Site | North Sydney | New South Wales |
| Australia | Research Site | Woodville South | South Australia |
| Brazil | Research Site | Barretos | São Paulo |
| Brazil | Research Site | Florianopolis | Santa Catarina |
| Brazil | Research Site | Rio de Janeiro | |
| France | Research Site | Dijon | |
| France | Research Site | Marseille cedex 05 | |
| France | Research Site | Paris | |
| France | Research Site | Pierre Benite Cedex | |
| France | Research Site | Toulouse cedex 9 | |
| Greece | Research Site | Athens | |
| Greece | Research Site | Heraklion - Crete | |
| Poland | Research Site | Poznan | |
| Poland | Research Site | Warszawa | |
| Poland | Research Site | Wroclaw | |
| Russian Federation | Research Site | Moscow | |
| Russian Federation | Research Site | Saint-Petersburg | |
| Russian Federation | Research Site | Saint-Petersburg | |
| Spain | Research Site | Madrid | |
| Spain | Research Site | Malaga | Andalucía |
| Spain | Research Site | Pamplona | Navarra |
| Switzerland | Research Site | Chur | |
| Switzerland | Research Site | Zürich | |
| United States | Research Site | Birmingham | Alabama |
| United States | Research Site | Chapel Hill | North Carolina |
| United States | Research Site | Columbus | Ohio |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Dallas | Texas |
| United States | Research Site | Daytona Beach | Florida |
| United States | Research Site | Duarte | California |
| United States | Research Site | Gainesville | Florida |
| United States | Research Site | Houston | Texas |
| United States | Research Site | Louisville | Kentucky |
| United States | Research Site | Memphis | Tennessee |
| United States | Research Site | New Brunswick | New Jersey |
| United States | Research Site | New York | New York |
| United States | Research Site | New York | New York |
| United States | Research Site | Omaha | Nebraska |
| United States | Research Site | Orange | California |
| United States | Research Site | Philadelphia | Pennsylvania |
| United States | Research Site | Salt Lake City | Utah |
| United States | Research Site | San Francisco | California |
| United States | Research Site | Santa Monica | California |
| United States | Research Site | Tampa | Florida |
| United States | Research Site | Worcester | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Amgen |
United States, Australia, Brazil, France, Greece, Poland, Russian Federation, Spain, Switzerland,
Dummer R, Gyorki DE, Hyngstrom J, Berger AC, Conry R, Demidov L, Sharma A, Treichel SA, Radcliffe H, Gorski KS, Anderson A, Chan E, Faries M, Ross MI. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat Med. 2021 Oct;27(10):1789-1796. doi: 10.1038/s41591-021-01510-7. Epub 2021 Oct 4. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Recurrence-Free Survival (RFS) | Recurrence free survival (RFS) is defined as the time from randomization to the date of event, and is presented as a Kaplan Meier estimate of time to events. The event for RFS is defined as the first of local, regional, or distant recurrence of melanoma or death due to any cause. Participants without a histopathology tumor-free margin (R0) surgical outcome or those who withdrew prior to surgery were considered an event at randomization. Participants without an event were censored at their last evaluable tumor assessment. | 24 months after last participant was randomized (data cutoff date of 30 April 2019) | |
| Secondary | RFS | Recurrence free survival (RFS) is defined as the time from randomization to the date of event, and is presented as a Kaplan Meier estimate of time to events. The event for RFS is defined as the first of local, regional, or distant recurrence of melanoma or death due to any cause. Participants without a histopathology tumor-free margin (R0) surgical outcome or those who withdrew prior to surgery were considered an event at randomization. Participants without an event were censored at their last evaluable tumor assessment. | 5 years after the last participant was randomized (last subject last visit occurred 28 April 2022) | |
| Secondary | Kaplan-Meier (K-M) Estimate of RFS Rate at 1 Year, 2 Years, 3 Years, and 5 Years | Kaplan-Meier estimates of the percentage of participants with RFS at 1 year, 2 years, 3 years, and 5 years from randomization. The event for RFS is defined as the first of local, regional, or distant recurrence of melanoma or death due to any cause. Participants without an R0 surgical outcome or those who withdrew prior to surgery are considered an event at randomization. Participants without an event were censored at their last evaluable tumor assessment. Rate is presented as the percentage of participants with RFS at given time point. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Histopathology Tumor-Free Margin (R0) Surgical Resection Rate | Histopathology tumor-free margin (R0) surgical resection is defined by pathologist as absence of ink on the tumor for all disease. Rate is presented as the percentage of participants with histopathology tumor-free margin (R0) surgical resection. | 18 weeks after last participant randomized (data cutoff date of 30 April 2019) | |
| Secondary | Pathological Complete Response (pCR) Rate | Pathological Complete Response (pCR) is defined as no evidence of viable tumor cells on complete pathological evaluation of the surgical specimen per institutional standards of care. Rate is presented as the percentage of participants with pCR. | 18 weeks after last participant randomized (data cutoff date of 30 April 2019) | |
| Secondary | Local Recurrence-Free Survival (LRFS) | Local recurrence-free survival (LRFS) is defined as the time from randomization to the earlier date of the first of local disease recurrence or death due to any cause. Participants without an R0 surgical outcome or those who withdrew prior to surgery are considered an event at randomization. Local recurrence is defined as histologically or cytologically confirmed reappearance of melanoma in the area of up to 2 cm from the scar from the surgical excision or at the edge of the skin graft if that was used for closure. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Regional Recurrence-Free Survival (RRFS) | Regional recurrence-free survival (RRFS) is defined as the time from randomization to the date of the first of regional disease recurrence or death due to any cause. Participants without an R0 surgical outcome or those who withdrew prior to surgery are considered an event at randomization. Regional recurrence excludes local recurrence and is defined as histologically, cytologically, or radiographically confirmed reappearance of melanoma in the regional lymph node basin. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Distant Metastases-Free Survival (DMFS) | Distant metastases-free survival (DMFS) is defined as the time from randomization to the date of the first of distant metastases or death due to any cause. Participants without an R0 surgical outcome or those who withdrew prior to surgery are considered an event at randomization. Distant metastases exclude local and regional recurrence and will include distant cutaneous/subcutaneous metastases, distant nodal metastases, or visceral, central nervous system, brain, or bone metastases. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Overall Survival (Kaplan-Meier) | Overall Survival (OS) is defined as the time from randomization to the date of death due to any cause. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Kaplan-Meier Estimate of OS at 1 Year, 2 Years, 3 Years, and 5 Years | Kaplan-Meier estimates of the percentage of participants alive at 1 year, 2 years, 3 years, and 5 years from randomization. | 5 years after the last participant was randomized (last subject last visit occurred on 28 April 2022) | |
| Secondary | Best Overall Tumor Response Per Investigator Response Rate (Talimogene Laherparepvec Arm Only) | Response was assessed based on the response of the index lesions and nonindex lesions as described in protocol-defined World Health Organization (WHO) criteria (for complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]), and presence or absence of new lesions. Best response for a participant is the best overall response observed across all time points. Response rate is reported as the percentage of participants with the best overall response (per investigator) of CR or PR. CR: complete disappearance of all index lesions, including any new measurable tumor lesions which might have appeared. PR: = 50% reduction in the sum of the products of the 2 largest perpendicular diameters of all index lesions and new measurable lesions, if applicable, at the time of assessment as compared to the sum of the products of the perpendicular diameters of all index lesions at baseline. | 18 months after last participant randomized (data cutoff date of 30 April 2019). | |
| Secondary | Lesion Objective Response Rate: Injected Lesions (Talimogene Laherparepvec Arm Only) | The investigator-assessed tumor response rate for injected lesions, reported as the percentage of evaluable lesions in response. A lesion is in response if the decrease in tumor area is = 50%. | 18 months after last participant randomized (data cutoff date of 30 April 2019). | |
| Secondary | Lesion Objective Response Rate: Uninjected Lesions (Talimogene Laherparepvec Arm Only) | The investigator-assessed tumor response rate for uninjected lesions, reported as the percentage of evaluable lesions in response. A lesion is in response if the decrease in tumor area is = 50%. | 18 months after last participant randomized (data cutoff date of 30 April 2019). | |
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Fatal Adverse Events (AEs), and TEAEs Leading to Discontinuations or Interruptions | Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. SAE: AE meeting at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Event severity grades: 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). Treatment begins when the first dose of protocol-required therapies is administered to a participant (Talimogene Laherparepvec Arm) or the participant undergoes surgery (Surgery Arm). Events are reported from first day of study drug or the surgery through 30 days after the last administration of talimogene laherparepvec or 30 days after the surgical resection of melanoma tumor lesion(s), whichever is later. | Adverse Events are reported from first day of study drug or the surgery through 30 days after the last dose of study drug or 30 days after the surgery, whichever is later. Median duration of treatment was 11.14 weeks (range 0.1 to 12.3 weeks). | |
| Secondary | Number of Participants With Talimogene Laherparepvec-Related TEAEs, SAEs, Fatal AEs, and TEAEs Leading to Discontinuations or Interruptions | Adverse event (AE): any untoward medical occurrence that does not necessarily have a causal relationship with study treatment. SAE: AE meeting at least 1 of the following serious criteria: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Event severity grades: 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). Treatment begins when the first dose of protocol-required therapies is administered to a participant (Talimogene Laherparepvec Arm) or the participant undergoes surgery (Surgery Arm). Events are reported from first day of study drug or the surgery through 30 days after the last administration of talimogene laherparepvec or 30 days after the surgical resection of melanoma tumor lesion(s), whichever is later. | Adverse Events are reported from first day of study drug or the surgery through 30 days after the last administration of talimogene laherparepvec or 30 days after the surgical resection of melanoma tumor lesion(s), whichever is later. |